<DOC>
	<DOCNO>NCT02577445</DOCNO>
	<brief_summary>The aim post market study assess impact sleep-disordered breathe well-being patient accord treatment chosen , i.e . without implantation remedē® system treat sleep-disordered breathing .</brief_summary>
	<brief_title>The remedē® System Treatment Central Sleep Apnea Daily Practice</brief_title>
	<detailed_description>The sponsor study , LivaNova , partnership Respicardia , Inc develop battery-powered implantable device treat central sleep apnea . The device use lead delivers stimulation therapy cause patient breathe regular rhythm optional lead sens breathe . This combination call remedē® system . The aim study 1. collect data order get good understand characteristic and/or symptom related central sleep apnea 2. collect safety information patient diagnosed central sleep apnea 3. obtain additional short lang term information safety performance remedē® system , include evaluation 's impact quality life patient treat remedē® system daily practice . The information obtain study may provide good insight symptom related central sleep apnea , risk factor related central sleep apnea therapy use remedē® system may help treat patient potential sleep disorder breathe appropriately . Approximately 300 patient ( ) implant remedē® system participate study approximately 40 site Europe . For purpose investigator aim screen approximately 1500 patient sleep-disordered breathing . Also patient diagnose central sleep apnea , receive device follow phone call 2 year .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Central</mesh_term>
	<criteria>All patient screen sleep disorder breathing Age &gt; 18 year Signed Ethics Committee approve informed consent Implant Inclusion criterion Diagnosis moderate severe central sleep apnea refer implant remedē system / implant remedē system Implant Patients meet criterion refer late version implant manual</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>